• Precision Medicine AI Agent Platform
          • Precision Medicine AI Agent Platform
          • Security & Compliance
        • Solutions
          • Overview
          • Agent Intelligence (AI)
          • Sample Intelligence (SI)
          • Biomarker Intelligence (BI)
        • Resources
          • News & Insights
          • Webinars & Events
          • FAQs
          • Case Studies
          • Literature
        • About Us
          • Overview
          • Leadership
          • Careers
          • Contact Us
  • Search
  • Menu Menu
Precision Medicine AI Agent Platform Solutions
Log in Book A Demo
Managing Complex Biomarker Data

Using Selection Biomarkers to Drive Clinical Trial Success

March 4, 2019 — Since the turn of the century, the use of biomarkers in drug discovery and development has exploded at an unprecedented rate. Recent scientific and technologic breakthroughs allow biomarkers to be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process—at a fraction of the cost and with turnaround times unimaginable less than a decade ago. Chad Clark et al., of Precision for Medicine, identify how these advances are driving a paradigm shift in drug discovery and development.

The use of biomarkers in drug discovery and development has exploded at an unprecedented rate since the turn of the century. With recent scientific and technological breakthroughs—including genomics, advanced cellular and tissue profiling, and complex imaging—biomarkers can now be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process at a fraction of the cost and with turnaround times unimaginable less than a decade ago. These advances in precision medicine are driving a paradigm shift in drug discovery and development as innovators are now focusing on programs with narrow indications, shorter development times, and lower costs.

View the complete article here


Authors: Chad Clark | President, Scott Marshall, PhD| Managing Director, Cliff Culver | Senior Vice President

https://www.quartz.bio/wp-content/uploads/2024/08/File13.jpg 790 1024 QuartzBio Team https://www.quartz.bio/wp-content/uploads/2025/03/QuartzBio-Banner-Logo_Blue.svg QuartzBio Team2019-03-04 22:00:282019-03-04 22:00:28Using Selection Biomarkers to Drive Clinical Trial Success

Search

QuartzBio Logo_The Precision Medicine Intelligence Company _white
  • Precision Medicine AI Agent Platform
  • Solutions
  • Log In
  • Book a Demo
  • Resources
  • About Us

Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.

QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.

© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR

Web Design and Development by RainCastle Communications.

  • Precision Medicine AI Agent Platform
    • Precision Medicine AI Agent Platform
    • Security & Compliance
    • Back
  • Solutions
    • Overview
    • Agent Intelligence (AI)
    • Sample Intelligence (SI)
    • Biomarker Intelligence (BI)
    • Back
  • Resources
    • Resources
    • Webinars & Events
    • FAQs
    • Case Studies
    • Product Literature
    • Back
  • About Us
    • Overview
    • Leadership
    • Careers
    • Contact Us
    • Back
  • Login
  • Book a Demo

Contact App Support



Request Documentation